Cyclerion Stock Soars on $380M Merger with Korsana to Fight Alzheimer’s
Cyclerion stock surges after announcing a merger with Korsana Biosciences and $380M in new funding to advance a next-gen Alzheimer’s antibody.
/ 195 items
#XY Event-Driven Stocks↓
ORIC Shares Slide on Higher-Dose Side Effects — But 400mg Rinzimetostat Looks Best-in-Class
ORIC shares plunged after Phase 1b data showed higher side effects at 600mg rinzimetostat.
ImmunityBio Scores $100 Million Cash Boost – $75M Non-Dilutive – to Supercharge Global Expansion
ImmunityBio strengthens its balance sheet with $100 million financing, including $75M non-dilutive funding from Oberland Capital and $25M debt conversion.
Agios Moves Closer to Fast FDA Approval for New Sickle Cell Pill
Agios is pursuing accelerated FDA approval for mitapivat, a new oral pill for sickle cell disease. The RISE UP trial showed better hemoglobin levels, fewer pain crises, and good safety.
Caribou Biosciences Jumps as FDA Grants RMAT Designation to Off-the-Shelf CAR-T Therapy CB-011 for Multiple Myeloma
Caribou Biosciences stock surges after FDA grants RMAT designation to CB-011, its off-the-shelf allogeneic CAR-T for multiple myeloma. Phase 1 data: 92% ORR, 75% complete response in BCMA-naïve patients. More data expected 2026.
Scholar Rock Shares Jump as Apitegromab BLA Resubmitted to FDA for SMA Treatment
Scholar Rock resubmits its BLA for apitegromab to treat SMA. FDA acceptance expected in 30 days, PDUFA target late September 2026.